Definium Therapeutics, Inc.
DFTX
$42.63
-$1.27-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.41M | 17.74M | 14.06M | 14.69M | 11.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.08M | 59.22M | 47.58M | 45.67M | 40.90M |
| Operating Income | -75.08M | -59.22M | -47.58M | -45.67M | -40.90M |
| Income Before Tax | -158.99M | -77.10M | -50.44M | -67.27M | -42.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -158.99M | -77.10M | -50.44M | -67.27M | -42.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -158.99M | -77.10M | -50.44M | -67.27M | -42.74M |
| EBIT | -75.08M | -59.22M | -47.58M | -45.67M | -40.90M |
| EBITDA | -- | -- | -47.57M | -45.66M | -40.90M |
| EPS Basic | -1.44 | -0.71 | -0.50 | -0.78 | -0.50 |
| Normalized Basic EPS | -0.90 | -0.44 | -0.31 | -0.49 | -0.31 |
| EPS Diluted | -1.44 | -0.71 | -0.50 | -0.78 | -0.50 |
| Normalized Diluted EPS | -0.90 | -0.44 | -0.31 | -0.49 | -0.31 |
| Average Basic Shares Outstanding | 110.68M | 108.79M | 101.00M | 85.89M | 85.35M |
| Average Diluted Shares Outstanding | 110.68M | 108.79M | 101.00M | 85.89M | 85.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |